LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protein Particle Parameters Help Differentiate Acute Kawasaki Disease

By LabMedica International staff writers
Posted on 28 Sep 2016
Print article
Image: The metabolic profiler system based on nuclear magnetic resonance (NMR) and mass spectrometry (MS) (Photo courtesy of Bruker BioSpin).
Image: The metabolic profiler system based on nuclear magnetic resonance (NMR) and mass spectrometry (MS) (Photo courtesy of Bruker BioSpin).
Kawasaki disease (KD) is a self-limited vasculitis that typically presents in young children as an acute illness with fever and mucocutaneous changes. If KD is incorrectly diagnosed or left untreated, coronary artery aneurysms (CAA) may develop, predisposing KD patients to long-term cardiovascular complications including myocardial ischemia and infarction.

Glycosylation patterns of serum proteins, such as α1-acid glycoprotein, are modified during an acute phase reaction. The response of acute KD patients to intravenous immunoglobulin (IVIG) treatment has been linked to sialic acid levels on native IgG, suggesting that protein glycosylation patterns vary during the immune response in acute KD.

Scientists at Rady Children’s Hospital (San Diego, CA, USA) and their colleagues enrolled 75 children diagnosed with KD according to established criteria and treated at Rady Children’s Hospital between November 2005 and June 2011. Forty-eight age-similar, healthy children undergoing minor orthopedic surgical procedures and 48 febrile children with acute illnesses of viral or bacterial origin were also included in the study as healthy or febrile controls.

White blood cell count (WBC), absolute neutrophil count (ANC), percent polymorphonuclear cells (PMN), high sensitivity C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured as part of clinical care. Nuclear magnetic resonance (NMR) spectra were acquired from EDTA plasma for the NMR LipoProfile (lipoprotein particle) test at LipoScience (now LabCorp, Raleigh, NC, USA). The NMR Profiler platform is comprised of a 9.4T (400 MHz 1H frequency) spectrometer (Bruker Biospin, Fremont, CA, USA) with an integrated fluidics sample delivery system.

GlycA, a marker of protein glycosylation, was elevated in acute KD subjects compared to febrile controls with bacterial or viral infections, IVIG-treated subacute and convalescent KD subjects, and healthy children. Acute KD subjects had increased total and small low density lipoprotein particle numbers (LDL-P) (and decreased total high density lipoprotein particle number (HDL-P) compared to febrile controls. Consequently, the ratio of LDL-P to HDL-P was higher in acute KD subjects than all groups tested. While GlycA, CRP, ESR, LDL-P and LDL-P/HDL-P ratio were able to distinguish patients with KD from those with other febrile illnesses, the combinations of GlycA and LDL-P or GlycA and the LDL-P/HDL-P ratio were best at discerning KD in patients 6 to 10 days after illness onset.

The authors concluded that high levels of GlycA confirm enhanced protein glycosylation as part of the acute phase response in KD patients. When combined with common laboratory tests and clinical characteristics, GlycA and NMR-measured lipoprotein particle parameters may be useful for distinguishing acute KD from bacterial or viral illnesses in pediatric patients. The study was published on September 5, 2016, in the journal BMC Pediatrics.

Related Links:
Rady Children’s Hospital
LabCorp
Bruker Biospin
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.